Zeneca Limited

E.i. Dupont De Nemours and Company

Astrazeneca Ab

The Dupont Merck Pharmaceutical Company

Compact Membrane Systems, Inc.

Ashokkumar Bhikkappa Shenvi

Scott Carson Miller

Chris Allan Veale

Robert T Jacobs

Cyrus J Ohnmacht

Robert Toms Jacobs

Charles A Kettner

Cyrus Ohnmacht

Michael H Wood

Engelbert Ciganek

Peter Robert Bernstein

Steven Sigmund Wesolowski

Dean Brown

Phil Edwards

Jeffrey Albert

Keith Russell

James Hulsizer

Dan Widzowski

James R Damewood

James Campbell Muir

M Edward Pierson, Jr

Andrew Edward Feiring

Peter R Bernstein

Donald J Wolanin

Peter Warner

James Woods

Thomas Richard Simpson

Andrew Shaw

Royston M Thomas

Ning Shangguan

James Rosamond

Bruce Thomas Dembofsky

James Kang

Christopher Becker

Philip Duke Edwards

Michael Wood

M Edward Pierson Jr

A highly fluorinated polymer is very useful as an acid catalyst. The highly fluorinated polymer has at least two repeating unit types that are the polymerized derivatives of a perfluorinated cyclic or cyclizable compound and a highly fluorinated vinyl ether compound having a sulfur containing functional group. The polymer can be formed by radical copolymerization of the fluorinated monomers with the sulfur-containing functional group in sulfonyl fluoride form (&#x2014;SOF) that is subsequently converted to sulfonic acid form (&#x2014;SOH). The highly fluorinated polymer can be used to advantage in a solution comprising an aprotic, polar organic solvent that has a dielectric constant of at least 15 and preferably is free of hydroxyl functional groups. Suitable solvents are those in which the polymer is soluble to at least 1 wt %. Hydroxyl group-containing protic, polar organic solvents are less preferred. The highly fluorinated polymer can be an effective heterogeneous catalysts when used in form of solid, fine particles insolubly suspended in or in contact with a fluid reaction mass.

Polymeric acid catalysis

Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.

Dibenzothiazepine derivatives and uses thereof&#x2014;424

Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid &#x3b2; protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit &#x3b3; secretase and thereby inhibit the production of amyloid &#x3b2; protein, thereby acting to prevent the formation of neurological deposits of amyloid protein. 

Lactams and uses thereof

The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R, R, R, R, R, R, R, R, R, R, X, X, Y, Z, and n are as defined herein), which are useful, for example, for antagonizing the pharmacological actions of the neurokinin 1 (NK) receptor. In particular, these compounds are useful in the treatment of diseases in which Substance P is involved such as, for example, major depressive disorder, severe anxiety disorders, stress disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety, mania or hypomania, aggressive behaviour, obesity, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, Huntington's disease, chronic obstructive pulmonary disorder (COPD), hypertension, migraine, bladder hypermotility, and urticaria.

Neurokinin antagonists for use as medicaments

A compound having the general formulaand methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.

Compounds

Compounds having the general formulawherein R, R, R, R, R, R, R, R, R, R, X, X, Y, Z and n are as defined in the specification, methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.

Substituted heterocycles

Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, Q.sup.4 and Q.sup.5 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists NKA, useful for the treatment of asthma etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Cyclic amide derivatives for treating asthma

Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, Q.sup.4 and Q.sup.5 have any of the meanings given in the specification, their N-oxides, and their pharmacuetically acceptable salts are nonpeptide antagonists NKA, useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Substituted piperidinobutyl nitrogen-containing heterocyclic compounds

The present invention relates to certain novel substituted derivatives which are 1-pyrimidinylacetamide derivatives of formula I, ##STR1## which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these substituted derivatives, processes for preparing the substituted derivatives, pharmaceutical compositions containing such substituted derivatives and methods for their use.

1-pyrimidinylacetamide compounds which are inhibitors of human leukocyte

Growing community of inventors

Wilmington, DE, United States of America

Ashokkumar Bhikkappa Shenvi